结直肠癌共识分子亚型与FIRE-3试验一线治疗疗效分析
FIRE-3试验纳入592例KRAS外显子2野生型转移性结直肠癌患者,比较FOLFIRI联合西妥昔单抗或贝伐珠单抗一线治疗。本探索性分析对438例可分类样本进行CMS分型,发现CMS是预后因素,西妥昔单抗组OS优势可能由CMS3和CMS4驱动。
要点
- CMS分型可评估的438例中,CMS2最常见(37%),CMS4占34%。
- CMS是ORR(P=0.051)、PFS(P<0.001)和OS(P<0.001)的强预后因素。
- RAS野生型CMS4中,FOLFIRI联合西妥昔单抗的OS显著优于联合贝伐珠单抗。
核心结论
- CMS分型对mCRC具有预后价值。
- FIRE-3中西妥昔单抗组OS延长可能由CMS3和CMS4驱动。
- CMS分型目前对临床决策无直接影响。
研究设计与样本
- FIRE-3(AIO KRK-0306)试验的探索性分析,纳入592例KRAS外显子2野生型mCRC患者。
- 514例有标本,438例可确定CMS分类。
- 比较FOLFIRI联合西妥昔单抗或贝伐珠单抗一线治疗。
主要发现
- 438例中CMS1占14%、CMS2占37%、CMS3占15%、CMS4占34%。
- 315例RAS野生型中CMS1占12%、CMS2占41%、CMS3占11%、CMS4占34%。
- 右半 vs 左半原发肿瘤CMS分布:CMS1 27% vs 11%,CMS2 28% vs 45%,CMS3 10% vs 12%,CMS4 35% vs 32%。
- CMS对ORR(P=0.051)、PFS(P<0.001)、OS(P<0.001)为强预后因素。
- RAS野生型CMS4中,FOLFIRI联合西妥昔单抗的OS显著优于联合贝伐珠单抗;CMS3中OS趋势 favoring 西妥昔单抗;CMS1和CMS2中OS相当。
临床怎么用
- CMS分型可用于预后评估和生物学理解。
- 目前CMS分型尚不能直接指导mCRC一线靶向治疗选择。
局限性
- 为探索性分析,CMS分型仅在438/514例标本中可确定。
- CMS分型目前对临床决策无直接影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to their gene-signature in four different subtypes. Relevance of CMS for the treatment of mCRC has yet to be defined. PATIENTS AND METHODS: In this exploratory analysis, patients were grouped according to the previously published tumor CRC-CMSs. Objective response rates (ORR) were compared using chi-square test. Overall survival (OS) and progression-free survival (PFS) times were compared using Kaplan-Meier estimation, log-rank tests. Hazard ratios (HR) were estimated according to the Cox proportional hazard method. RESULTS: CMS classification could be determined in 438 out of 514 specimens available from the intent-to-treat (ITT) population (n = 592). Frequencies for the remaining 438 samples were as follows: CMS1 (14%), CMS2 (37%), CMS3 (15%), CMS4 (34%). For the 315 RAS wild-type tumors, frequencies were as follows: CMS1 (12%), CMS2 (41%), CMS3 (11%), CMS4 (34%). CMS distribution in right- versus (vs) left-sided primary tumors was as follows: CMS1 (27% versus 11%), CMS2 (28% versus 45%), CMS3 (10% versus 12%), CMS4 (35% versus 32%). Independent of the treatment, CMS was a strong prognostic factor for ORR (P = 0.051), PFS (P < 0.001), and OS (P < 0.001). Within the RAS wild-type population, OS observed in CMS4 significantly favored FOLFIRI cetuximab over FOLFIRI bevacizumab. In CMS3, OS showed a trend in favor of the cetuximab arm, while OS was comparable in CMS1 and CMS2, independent of targeted therapy. CONCLUSIONS: CMS classification is prognostic for mCRC. Prolonged OS induced by FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab in the FIRE-3 study appears to be driven by CMS3 and CMS4. CMS classification provides deeper insights into the biology to CRC, but at present time has no direct impact on clinical decision-making.The FIRE-3 (AIO KRK-0306) study had been registered at ClinicalTrials.gov: NCT00433927.
引用
- Stintzing S, Wirapati P, Lenz HJ, et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol. 2019. PMID: 31868905. doi:10.1093/annonc/mdz387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。